Compare · ESPR vs LLY
ESPR vs LLY
Side-by-side comparison of Esperion Therapeutics Inc. (ESPR) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ESPR and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.09T, about 1324.5x ESPR ($819.5M).
- Over the past year, ESPR is up 182.3% and LLY is up 49.6% - ESPR leads by 132.7 points.
- ESPR has been more active in the news (39 items in the past 4 weeks vs 8 for LLY).
- Both have 25 recent analyst ratings on file.
- Company
- Esperion Therapeutics Inc.
- Eli Lilly and Company
- Price
- $3.19+0.16%
- $1154.26-2.51%
- Market cap
- $819.5M
- $1.09T
- 1M return
- +1.59%
- -0.54%
- 1Y return
- +182.30%
- +49.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2013
- News (4w)
- 39
- 8
- Recent ratings
- 25
- 25
Esperion Therapeutics Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest ESPR
- Amendment: SEC Form SCHEDULE 13G/A filed by Esperion Therapeutics Inc.
- Director Hoffman Robert E. returned 85,153 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover withholding tax
- Director Carroll J Martin returned 177,523 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover withholding tax
- Director Shepard Jay returned 164,472 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy tax liability
- Director Fischer Seth H. Z. returned 141,023 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)
- Director Thompson John Craig returned 79,873 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)
- Chief Commercial Officer Harlow John B. Jr. returned 424,536 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Chief Legal Officer Looker Benjamin returned 667,524 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Chief Financial Officer Halladay Benjamin returned 705,410 shares to the company, closing all direct ownership in the company (SEC Form 4) (for tax liability)
- President and CEO Koenig Sheldon L. returned 2,121,094 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)
Latest LLY
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend
- International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.15% to 2,995 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,891 units (SEC Form 4)